BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 28422713)

  • 1. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains.
    Rzymski T; Mikula M; Żyłkiewicz E; Dreas A; Wiklik K; Gołas A; Wójcik K; Masiejczyk M; Wróbel A; Dolata I; Kitlińska A; Statkiewicz M; Kuklinska U; Goryca K; Sapała Ł; Grochowska A; Cabaj A; Szajewska-Skuta M; Gabor-Worwa E; Kucwaj K; Białas A; Radzimierski A; Combik M; Woyciechowski J; Mikulski M; Windak R; Ostrowski J; Brzózka K
    Oncotarget; 2017 May; 8(20):33779-33795. PubMed ID: 28422713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MK256 is a novel CDK8 inhibitor with potent antitumor activity in AML through downregulation of the STAT pathway.
    Lee JC; Liu S; Wang Y; Liang Y; Jablons DM
    Oncotarget; 2022 Nov; 13():1217-1236. PubMed ID: 36342456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
    Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
    Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells.
    Saenz DT; Fiskus W; Manshouri T; Rajapakshe K; Krieger S; Sun B; Mill CP; DiNardo C; Pemmaraju N; Kadia T; Parmar S; Sharma S; Coarfa C; Qiu P; Verstovsek S; Bhalla KN
    Leukemia; 2017 Mar; 31(3):678-687. PubMed ID: 27677740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective and Potent CDK8/19 Inhibitors Enhance NK-Cell Activity and Promote Tumor Surveillance.
    Hofmann MH; Mani R; Engelhardt H; Impagnatiello MA; Carotta S; Kerenyi M; Lorenzo-Herrero S; Böttcher J; Scharn D; Arnhof H; Zoephel A; Schnitzer R; Gerstberger T; Sanderson MP; Rajgolikar G; Goswami S; Vasu S; Ettmayer P; Gonzalez S; Pearson M; McConnell DB; Kraut N; Muthusamy N; Moll J
    Mol Cancer Ther; 2020 Apr; 19(4):1018-1030. PubMed ID: 32024684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aurora kinase inhibitor restrains STAT5-activated leukemic cell proliferation by inducing mitochondrial impairment.
    Wang JX; Zhang L; Huang ZW; Zhang XN; Jiang YY; Liu FJ; Long L; Xue MJ; Lu G; Liu Q; Long ZJ
    J Cell Physiol; 2020 Nov; 235(11):8358-8370. PubMed ID: 32239704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CDK8 kinase phosphorylates transcription factor STAT1 to selectively regulate the interferon response.
    Bancerek J; Poss ZC; Steinparzer I; Sedlyarov V; Pfaffenwimmer T; Mikulic I; Dölken L; Strobl B; Müller M; Taatjes DJ; Kovarik P
    Immunity; 2013 Feb; 38(2):250-62. PubMed ID: 23352233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells.
    Tong H; Ren Y; Zhang F; Jin J
    Eur J Haematol; 2008 Oct; 81(4):259-66. PubMed ID: 18616510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Toxicity Reported for CDK8/19 Inhibitors CCT251921 and MSC2530818 Is Not Due to Target Inhibition.
    Chen M; Li J; Liang J; Thompson ZS; Kathrein K; Broude EV; Roninson IB
    Cells; 2019 Nov; 8(11):. PubMed ID: 31717492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mediator Kinase Phosphorylation of STAT1 S727 Promotes Growth of Neoplasms With JAK-STAT Activation.
    Nitulescu II; Meyer SC; Wen QJ; Crispino JD; Lemieux ME; Levine RL; Pelish HE; Shair MD
    EBioMedicine; 2017 Dec; 26():112-125. PubMed ID: 29239838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angel or Devil ? - CDK8 as the new drug target.
    Wu D; Zhang Z; Chen X; Yan Y; Liu X
    Eur J Med Chem; 2021 Mar; 213():113043. PubMed ID: 33257171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-1β inhibits self-renewal capacity of dormant CD34⁺/CD38⁻ acute myelogenous leukemia cells in vitro and in vivo.
    Yang J; Ikezoe T; Nishioka C; Nobumoto A; Yokoyama A
    Int J Cancer; 2013 Oct; 133(8):1967-81. PubMed ID: 23564444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New CDK8 inhibitors as potential anti-leukemic agents - Design, synthesis and biological evaluation.
    Solum E; Hansen TV; Aesoy R; Herfindal L
    Bioorg Med Chem; 2020 May; 28(10):115461. PubMed ID: 32245563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Shape-based virtual screen for the discovery of novel CDK8 inhibitor chemotypes.
    He LJ; Zhu YB; Fan QZ; Miao DD; Zhang SP; Liu XP; Zhang C
    Bioorg Med Chem Lett; 2019 Feb; 29(4):549-555. PubMed ID: 30630717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PIM inhibitors target CD25-positive AML cells through concomitant suppression of STAT5 activation and degradation of MYC oncogene.
    Guo Z; Wang A; Zhang W; Levit M; Gao Q; Barberis C; Tabart M; Zhang J; Hoffmann D; Wiederschain D; Rocnik J; Sun F; Murtie J; Lengauer C; Gross S; Zhang B; Cheng H; Patel V; Schio L; Adrian F; Dorsch M; Garcia-Echeverria C; Huang SM
    Blood; 2014 Sep; 124(11):1777-89. PubMed ID: 25006129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The transcription factor STAT5 catalyzes Mannich ligation reactions yielding inhibitors of leukemic cell proliferation.
    Wong EL; Nawrotzky E; Arkona C; Kim BG; Beligny S; Wang X; Wagner S; Lisurek M; Carstanjen D; Rademann J
    Nat Commun; 2019 Jan; 10(1):66. PubMed ID: 30622248
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potent and orally bioavailable CDK8 inhibitors: Design, synthesis, structure-activity relationship analysis and biological evaluation.
    Yu M; Teo T; Yang Y; Li M; Long Y; Philip S; Noll B; Heinemann GK; Diab S; Eldi P; Mekonnen L; Anshabo AT; Rahaman MH; Milne R; Hayball JD; Wang S
    Eur J Med Chem; 2021 Mar; 214():113248. PubMed ID: 33571827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?
    Philip S; Kumarasiri M; Teo T; Yu M; Wang S
    J Med Chem; 2018 Jun; 61(12):5073-5092. PubMed ID: 29266937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. All-Atomic Molecular Dynamic Studies of Human and
    Xu W; Xie XJ; Faust AK; Liu M; Li X; Chen F; Naquin AA; Walton AC; Kishbaugh PW; Ji JY
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.